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Following the discovery that the amyloid precursor protein (APP) is the source of
β-amyloid peptides (Aβ) that accumulate in Alzheimer’s disease (AD), structural analyses
suggested that the holoprotein resembles a transmembrane receptor. Initial studies
using reconstituted membranes demonstrated that APP can directly interact with
the heterotrimeric G protein Gαo (but not other G proteins) via an evolutionarily G
protein-binding motif in its cytoplasmic domain. Subsequent investigations in cell
culture showed that antibodies against the extracellular domain of APP could stimulate
Gαo activity, presumably mimicking endogenous APP ligands. In addition, chronically
activating wild type APP or overexpressing mutant APP isoforms linked with familial
AD could provoke Go-dependent neurotoxic responses, while biochemical assays
using human brain samples suggested that the endogenous APP-Go interactions are
perturbed in AD patients. More recently, several G protein-dependent pathways have
been implicated in the physiological roles of APP, coupled with evidence that APP
interacts both physically and functionally with Gαo in a variety of contexts. Work in
insect models has demonstrated that the APP ortholog APPL directly interacts with Gαo
in motile neurons, whereby APPL-Gαo signaling regulates the response of migratory
neurons to ligands encountered in the developing nervous system. Concurrent studies
using cultured mammalian neurons and organotypic hippocampal slice preparations
have shown that APP signaling transduces the neuroprotective effects of soluble
sAPPα fragments via modulation of the PI3K/Akt pathway, providing a mechanism for
integrating the stress and survival responses regulated by APP. Notably, this effect
was also inhibited by pertussis toxin, indicating an essential role for Gαo/i proteins.
Unexpectedly, C-terminal fragments (CTFs) derived from APP have also been found
to interact with Gαs, whereby CTF-Gαs signaling can promote neurite outgrowth
via adenylyl cyclase/PKA-dependent pathways. These reports offer the intriguing
perspective that G protein switching might modulate APP-dependent responses in a
context-dependent manner. In this review, we provide an up-to-date perspective on the
model that APP plays a variety of roles as an atypical G protein-coupled receptor in both
the developing and adult nervous system, and we discuss the hypothesis that disruption
of these normal functions might contribute to the progressive neuropathologies that
typify AD.
Keywords: Alzheimer’s disease, amyloid precursor protein, APPL, Drosophila, Gαo, Manduca, migration, stress
signaling
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APP AS AN UNCONVENTIONAL G
PROTEIN-COUPLED RECEPTOR:
HISTORICAL PERSPECTIVE
Members of the APP family share many of the structural
features that distinguish type-1 transmembrane receptors,
including evolutionarily conserved extracellular domains capable
of binding a variety of candidate ligands, plus highly conserved
intracellular domains that can mediate interactions with
numerous cytoplasmic adapter and signaling proteins (Turner
et al., 2003; Jacobsen and Iverfeldt, 2009; Deyts et al., 2016b).
In addition, APP is also capable of both homodimeric binding
(to itself) and heterodimeric interactions with two APP-like
proteins (APLP1 and APLP2) and other membrane-associated
proteins (Scheuermann et al., 2001; Soba et al., 2005; Wang
et al., 2009; Kaden et al., 2012), consistent with the perspective
that APP and its orthologs can function as neuronal receptors
that modulate both physiological and pathological responses.
Whereas receptors with the topology of APP are most commonly
associated with the activation of intracellular kinases (Heldin
et al., 2016; Trenker et al., 2016), a growing number of single-
pass receptors have now been shown to function as authentic
G protein-coupled receptors (GPCRs) that mediate cellular
responses via heterotrimeric G proteins, including Fibroblast
Growth Factor and Epidermal Growth Factor Receptors (Patel,
2004; Hawkes et al., 2007). Based on the identification of a short
motif in Insulin-like Growth Factor II receptor that binds the
heterotrimeric G protein Gi (Okamoto et al., 1990), Nishimoto
et al. (1993) identified a similar motif in APP (Figure 1A;
described below), suggesting that APP might also function as
G protein-interacting receptor. Specifically, they identified a
20 amino acid peptide (“peptide 20”) within the intracellular
domain (His657-Lys676; numbering in APP695) that could directly
bind and activate heterotrimeric G proteins containing Gαo
but not other Gα subunits (including Gαs, Gαi1, Gαi2, and
Gαi3) in reconstituted membranes (Table 1). This effect was
blocked by PTX (a selective inhibitor of the Gαo/i subfamily).
They also demonstrated that the alpha subunit of Go (Gαo)
but not Gαi could be co-immunoprecipitated with APP from
concentrated brain membranes, an interaction that was inhibited
by adding excess peptide 20. Using membrane preparations from
Abbreviations: Aβ, beta-amyloid peptide derived from APP; AC, adenylyl cyclase;
AD, Alzheimer’s disease; AICD, APP intracellular domain cleavage fragments of
APP family proteins; Akt, target of PI3K (also called Protein kinase B); APP,
amyloid precursor protein; APP695, predominant isoform of APP in mammalian
neurons (695 amino acids); APLP1 and APLP2, APP-Like-Proteins 1 and 2
(additional APP family members expressed in the mammalian brain); APPL,
APP-Like, the insect ortholog of human APP; BiFC, bimolecular fluorescence
complementation; CaMKIV, calcium/calmodulin-dependent protein kinase IV;
cAMP, cyclic adenosine monophosphate; CREB, cAMP response element binding
protein; CTX; cholera toxin; FAD, familial AD; Gαi, alpha subunit of the
heterotrimeric G protein Gi; Gαo, alpha subunit of the heterotrimeric G
protein Go; Gβγ, beta/gamma dimeric subunits of heterotrimeric G proteins;
GSK3β, glycogen synthase kinase 3 beta; JNK, c-Jun N-terminal kinase; pCREB,
phosphorylated CREB; PI3K, phosphatidylinositol-4,5-bisphosphate 3-kinase;
PKA, protein kinase A; PS-1, presenilin-1; PS-2; presenilin 2; PTX, pertussis toxin,
a selective inhibitor of Gαi/Gαo family of heterotrimeric G proteins; sAPPα,
secreted ectodomain fragments of APP generated by α-secretase cleavage. sAPPL,
secreted ectodomain fragments of insect APPL (equivalent to sAPPα).
transfected SF9 cells, they then showed that APP695 could be
co-immunoprecipitated with purified bovine Go, in contrast to
mutated forms of APP lacking the peptide 20 domain (Nishimoto
et al., 1993). Of note is that Gβ could also be detected in
these immunoprecipitates, consistent with the model that APP
normally interacts with Go as a heterotrimeric complex (similar
to conventional GPCRs). Lastly, Gαo was shown to specifically
mediate the effects of peptide 20 on GTP hydrolysis, while pre-
treatment with GTPγS blocked this interaction (Lang et al., 1995),
indicating that the activation state of Go regulates its interaction
with APP (again consistent with conventional GPCRs).
In related experiments, Ikezu et al. (1996) co-expressed APP
with chimeric Gα subunits to demonstrate that the last five
amino acids of Gαo are necessary for its interactions with
APP, whereas chimeras containing the cytoplasmic domains
of other Gα subunits were ineffective (Table 1). This result
is consistent with extensive evidence that C-terminal residues
within Gα subunits control the specificity of their interactions
with conventional GPCRs (Hamm et al., 1988; Herrmann et al.,
2004). In collaboration with other groups, they also showed
that soluble peptide 20 could regulate Go-dependent exocytosis
but had no effect on Gs-dependent membrane fusion events,
further validating the model that APP specifically interacts with
the C-terminal region of Gαo (Colombo et al., 1994; Lang
et al., 1995). These results provide strong evidence that the
juxtamembrane G protein-binding domain in APP promotes
functional interactions with Gαo (but not other G proteins),
suggesting that APP might indeed function as an atypical Go-
coupled receptor.
Subsequent studies explored whether stimulating APP with an
antibody against its extracellular domain (22C11; to mimic ligand
binding) could induce Gαo activity. In liposomes containing
reconstituted APP695 and bovine Go, treatment with 22C11
induced the activation of Go (but not Gi2) in the absence
of other proteins (Okamoto et al., 1995, 1996). Although the
22C11 antibody can also detect APLP2 (Slunt et al., 1994),
other antibodies targeting different epitopes in APP (but not
APLP1 or APLP2) were also found to induce Go-associated
responses, including α-1680 and Alz90 (Sudo et al., 2000). In
this regard, several groups also tested whether the effects of APP
on Gαo signaling might be recapitulated by APLP1 or APLP2.
Although one study showed that antibody activation of either
APP or APLP2 could induce similar cytotoxic responses to 22C11
(Mbebi et al., 2002), other investigators used APP knockout
lines to show that only re-expression of APP rescued Gαo-
dependent responses, whereas expression of APLP1 and APLP2
did not (Sola Vigo et al., 2009; Milosch et al., 2014). Thus, these
studies provided intriguing evidence that only APP can function
as an unconventional Go-coupled receptor, albeit under rather
artificial conditions.
ABERRANT APP-Go SIGNALING CAN
PROVOKE NEURODEGENERATION
How might the misregulation of normal APP-Go signaling
contribute to the pathology of AD? To address this issue,
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FIGURE 1 | Defining the G protein-binding domains in APP family proteins. (A) Intracellular domain of human APP695, equivalent to the cytoplasmic AICD
fragment generated by γ-secretase processing. Magenta region indicates the “peptide 20” Go binding domain (H657-L676) originally identified by Nishimoto et al.
(1993); green region indicates the tyrosine-based sorting motif (YENPTY) that mediates interactions with many other cytosolic proteins. Asterisks indicate the
N-terminal HH doublet in the Go domain, while the BBXXB motif (RHLSK) is located at the C-terminus (compare with C). (B) Summary of the deletions used by
different investigators to map the sequences in APP that are required for its interaction with Gαo. Amino acids contained within the G protein-binding domain are
highlighted in magenta; the YENPTY domain is highlighted in green. Deletions that eliminated Gαo interactions (1B1, 1B3, 1B4, 1B5, 1B6, 1B8, 1B9) encompassed
some or all of the Go domain (indicated by light magenta box). Deletions that encompassed the YENPTY domain but not the Go domain did not affect Gαo
interactions (1B2, 1B7, 1B10, 1B11). In one study, deletions highlighted in yellow (1B12, 1B13) were found to interfere with APP-Gαo signaling but paradoxically not
with APP-Gαo interactions. Superscripted letters indicate citations for each deletion construct (summarized below). (C) Amino acid alignment of the G
protein-binding domains from human APP695, APLP1 and APLP2; plus APL-1 from Caenorhabditis elegans, APPL from Manduca sexta, and APPL from Drosophila
melanogaster (which contains an additional inserted sequence; shown below the alignment). Identical amino acids are indicated by color. Basic amino acids in that
align with (or near) the HH doublet in APP695 are highlighted in yellow. The boxed region indicates the BBXXB motif in APP695 (RHLSK), and the equivalent region in
other APP family proteins; only APLP2 also has a complete BBXXB motif (RHLNK). Asterisks indicate amino acids within the G protein-binding domains of APP695
and APLP1 that were found to be necessary for interactions between membrane-tethered AICDs or CTF fragments of the holoproteins and Gαs (Deyts et al., 2012).
(D) Deletions in APPL that interfere with Gαo-associated motile responses in developing neurons (1D1, 1D2) and prevent direct binding between APPL and Gαo
(1D2). Citations describing each deletion construct are as follows: aNishimoto et al., 1993; bOkamoto et al., 1996; c Ikezu et al., 1996; dYamatsuji et al., 1996a;
eYamatsuji et al., 1996b; fHashimoto et al., 2000; gSudo et al., 2001; hSola Vigo et al., 2009; iMilosch et al., 2014; jShaked et al., 2009; kTorroja et al., 1999b;
lRamaker et al., 2013.
Yamatsuji et al. (1996a,b) used COS cells expressing Go to
compare the responses elicited by wild type APP695 versus
APP containing missense mutations that are known to cause
early onset FAD. In contrast to wild type APP695, expression
of these “FAD-APP” mutant isoforms (including V642I, V642F,
V642G) induced a dramatic increase in DNA fragmentation and
apoptosis. This effect was blocked by PTX treatment (indicating
Gαo/i proteins) or by expressing a dominant-interfering form
of Gαo (Table 1), but was not affected by CTX (an activator
of Gαs) and was absent in COS cells lacking Go. Notably,
treatment with either synthetic Aβ40 or Aβ42 did not induce
apoptotic responses in this assay, nor did conditioned medium
harvested from cell cultures expressing the V642 mutant isoforms
(which produce abundant Aβ42). In combination, these studies
supported the model that mutated forms of APP linked with
FAD can indeed function as constitutively active Go-coupled
receptors. Moreover, they suggested that the pathophysiological
effects of FAD-APP mutations might be caused by aberrant
hyperactivation of Go-dependent signaling, rather than simply
promoting the accumulation of neurotoxic Aβ. An appealing
corollary to this model is that the downstream pathways regulated
by Go could provide novel biomarkers or therapeutic targets for
treating AD.
Unfortunately, attempts to identify these downstream
pathways produced paradoxical results. For example, using
COS cells co-expressing chimeric Gα subunits with different
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TABLE 1 | Evidence for functional interactions between APP family
proteins and heterotrimeric G proteins.
APP source G-protein Citation
APP695 wt; peptide 20
(H657-L676
Gαo∗; not Gαs,
Gαi1,2,3,
Nishimoto et al., 1993
Peptide 20 (H657-L676) Gαo/i; not Gαs Colombo et al., 1994;
Lang et al., 1995
APP695 wt Gαo∗; not Gαi2 Okamoto et al., 1995
APP695 wt Gαo∗ Okamoto et al., 1996
APP695 wt, V642 I,
V642F, V642G
Gαo∗#; not Gαs, Gαi2,
Gαz
Ikezu et al., 1996
APP695 V642 I, V642F,
V642G
Gαo#; not Gαi2 Yamatsuji et al., 1996a
APP695 V642 I, V642F,
V642G
Gαo; not Gαi2 Yamatsuji et al., 1996b
APP695 V642 I Gαo#; not Gαt Giambarella et al., 1997
APP695 wt Gαo∗#; not Gαi2 or
Gαs#
Brouillet et al., 1999
APP695 V642 I Gαo/i† Hashimoto et al., 2000
APP695 wt, V642 I Gαo/i† Sudo et al., 2000
APP695 wt, V642 I Gαo/i† Niikura et al., 2000
APP695 wt Gαo/i† Mbebi et al., 2002
APP695 wt Gαo; not Gαi1 Hashimoto et al., 2003a
EGFR-APPicd chimera Gαo/i† Hashimoto et al.,
2003b
APP695 V642 I, APP695
KM595−6NL
Gαo McPhie et al., 2003
APP695 wt, V642 I Gαo/i† Niikura et al., 2004
APP695 wt Gαo/i Xu et al., 2009
APP695 wt Gαo; not Gαi2, Gαi3, Sola Vigo et al., 2009
APP695 wt Gαo† Shaked et al., 2009
APPL (Manduca,
Drosophila)
Gαo∗; not Gαi, Gαs Ramaker et al., 2013
APP695 wt Gαo∗; not Gαs Ramaker et al., 2013
APP695 wt Gαo∗ Fogel et al., 2014
APP695 wt Gαo/i† Milosch et al., 2014
APPL (Manduca) Gαo Ramaker et al., 2016a
Membrane-tethered
AICD
Gαs∗∗ Deyts et al., 2012
Summary of published evidence that APP interacts with Gαo (but usually not
other G proteins, including Gαs, Gαz, and Gαi isofroms). The table includes
studies on both wild type APP695, isolated peptide 20 constructs (containing
the G protein-binding domain of APP695), and FAD-associated mutant forms of
APP with altered residues at V642 (indicated in the left-hand column). Studies
that showed direct binding between Gαo and APP/APPL are indicated with an
asterisk (∗). Studies that used PTX to indicate the involvement of Gαo/i family
proteins are indicated with a cross (†). Studies that used CTX to indicate the
absence of Gαs-dependent signaling is indicated with a hash mark (#). Study
that showed direct binding between Gαs and constructs containing the G protein-
binding domain is indicated with a double asterisk (∗∗). Citations for each set of
results are shown in the right-hand column. ∗Studies that showed direct binding
between Gαo and APP/APPL (or the G protein-binding domain). †Studies that
demonstrated sensitivity to PTX, indicating the involvement of Gαo/i. #Studies
that tested sensitivity to CTX, indicating the absence of Gαs-dependent signaling.
∗∗Study that showed direct binding between Gαs and peptides containing the G
protein-binding domain.
variants of APP, Ikezu et al. (1996) found that FAD-APP
isoforms inhibited cAMP response element (CRE)-mediated
transcription in a Gαo-specific manner. Curiously, this effect was
independent of adenylyl cyclase (AC) activity, while inhibitors
of Gβγ signaling (rather than Gαo) blocked apoptotic responses
in this assay (Giambarella et al., 1997). From these studies, the
authors concluded that APP signaling normally regulates both
Gαo- and Gβγ-dependent pathways, whereby Gαo regulates
CRE-dependent transcriptional responses, while Gβγ regulates
other effectors (as yet undefined) that can induce apoptosis
when chronically activated. More perplexing were the results
from another group, who found that 22C11 treatment in brain
membrane fractions actually inhibited Gαo-dependent responses
(Brouillet et al., 1999), leading to the proposal that unknown
proteins expressed by neurons but not glial-derived cells (or in
reconstituted membranes) might regulate Gαo activation by APP
(Brouillet et al., 1999; Sudo et al., 2000). How the misregulation
of Gαo- versus Gβγ-dependent pathways might contribute to
AD remained an open question.
NEUROTOXIC MECHANISMS OF
MISREGULATED APP- Gαo SIGNALING:
CONFLICTING MODELS
Subsequent investigations have generated an unexpectedly
complicated (and often contradictory) view of how the APP-
Go pathway might function in the diseased nervous system.
Using a variety of transfected cell lines, Nishimoto et al.
(1993) first confirmed that the induction of APP-Gαo signaling
(by antibody crosslinking or induced dimerization) required
transmembrane APP (Sudo et al., 2000; Hashimoto et al.,
2003a), and that hyperactivation of this pathway could induce
apoptotic responses in cultured mouse neurons (see also Rohn
et al., 2000). Both groups described classic features of neuronal
apoptosis in their assays, including neurite degeneration, nuclear
condensation, internucleosomal DNA cleavage, and activation of
pro-apoptotic caspases (including caspase 3, 7, and 9). Treatment
with inhibitors of glutathione metabolism or NADPH oxidase
(as well as incubation with antioxidants) effectively blocked
the cell death response, suggesting that hyperstimulation of
the APP-Gαo pathway induces a chronic elevation of reactive
oxygen species (ROS), resulting in the induction of caspase-
dependent apoptosis. Moreover, expressing FAD-APP isoforms
induced the same cytotoxic responses caused by hyperstimulating
wild type APP, including activation of ASK1 (Apoptosis Signal-
Regulating kinase) and its downstream effector JNK that resulted
in chronic upregulation of NADPH oxidase, elevated ROS
levels, and activation of pro-apoptotic caspases (Hashimoto
et al., 2003b; Niikura et al., 2004). A similar response could
be induced by expressing a chimeric protein containing the
dimerization domain of the EGF receptor fused with the
APP cytoplasmic domain, providing a plausible explanation for
how the hyperstimulation of normal APP-Go signaling with
crosslinking antibodies could provoke neuronal death in an
Aβ-independent manner. By comparison, the neurotoxic effects
of FAD-associated mutations within a different region of APP
(K595/M596) were found to be independent of Go, suggesting
that different disease-associated mutations in APP might perturb
a variety of signaling pathways that affect neuronal viability
(Hashimoto et al., 2000). Collectively, these results bolstered the
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argument that the aberrant APP-Go signaling might contribute
to both late-onset AD and some forms of FAD.
However, it should be noted that enforced dimerization of
APP (with crosslinked antibodies or chimeric fusion proteins)
involves rather artificial methods that may not recapitulate
authentic physiological or pathophysiological interactions.
Moreover, it is difficult to reconcile these results with more
recent evidence that ∼65% of membrane-bound APP in
healthy cells is normally present in a dimeric configuration
(Gralle et al., 2009). Nevertheless, these cytotoxic effects could
be recapitulated by overexpressing an FAD-APP isoform
(V642I-APP) in both neuroblastoma cells and primary neurons
(Niikura et al., 2000, 2004), independent of Aβ-associated
toxicity (Sudo et al., 2001). Alternatively, other groups have
suggested that forced dimerization of APP might provoke
Go-dependent apoptotic responses via a variety of other
pathways, including PAK3-dependent re-entry into the cell
cycle (McPhie et al., 2003), misregulation of Src-dependent
actin dynamics and focal adhesion turnover (Xu et al., 2009),
and calpain/calcineurin-dependent proteolysis of CaMKIV,
resulting in the misregulation of CREB (Mbebi et al., 2002).
Also problematic is the mechanism by which the APP-Go
pathway might actually stimulate JNK: although both the α
and βγ subunits of a number of heterotrimeric G proteins
(including Go) can modulate JNK activity in different contexts,
these responses typically require a cascade of other kinases
and adapter proteins that have not been implicated in APP-Go
signaling (Goldsmith and Dhanasekaran, 2007; Bromberg
et al., 2008; Yu et al., 2016). Lastly, all of these studies focused
on pathological outcomes that could be induced by aberrant
APP-Gαo signaling, but the authentic functions of this pathway
in the healthy nervous system remained largely unexplored.
As described below, recent studies from the Kögel laboratory
have now indicated that APP-Gαo signaling may actually
antagonize the JNK pathway under physiological conditions,
whereby the induction of APP signaling counteracts cellular
stress responses via the PI3K cascade, providing a mechanism
that promotes neuronal survival (Kögel et al., 2012; Milosch
et al., 2014).
IS APP-Gαo SIGNALING ALTERED IN
HUMAN PATIENTS WITH AD?
Whether the misregulation of APP-Go signaling actually plays
a role in provoking AD remains unknown. However, a variety
of studies have offered intriguing hints that support this
hypothesis. Initial reports using human brain samples revealed
that the expression patterns of many heterotrimeric G proteins
are altered in late sporadic AD, particularly within the most
vulnerable brain regions (including cortex and hippocampus).
These changes also correlate with a general reduction in G
protein-dependent GTP hydrolysis at stages that precede the
onset of clinical disease (O’Neill et al., 1994; Cowburn et al.,
2001; Garcia-Jimenez et al., 2002). Similarly, using reconstituted
membrane preparations from human brain samples, Mahlapuu
et al. (2003) found that the induction of G protein activity
by APP-derived peptides was significantly reduced in post-
mortem elderly AD patients compared to age-matched controls.
Recapitulating the original studies by Nishimoto et al. (1993),
they also found that membrane-tethered constructs of the Go
domain (peptide 20 plus the transmembrane T639-L649 sequence)
induced more robust [35S]GTPγS binding than soluble peptide
20 (Mahlapuu et al., 2003). Curiously, adding the transmembrane
peptide alone (T639-L649) also affected [35S]GTPγS binding, while
equivalent peptides containing V642 APP-FAD mutations were
even more effective (Karelson et al., 2005), although how these
hydrophobic constructs might interact with G proteins when
applied to isolated membranes is unclear. Nevertheless, these
results provided indirect evidence that disease-associated changes
in the GPCR-like function of APP might contribute to both FAD
and late-onset AD (as noted by the authors).
Perhaps because it is the most abundant G protein in the
brain (Strittmatter et al., 1990; Jiang and Bajpayee, 2009),
the overall levels of Gαo do not appear to be altered in
either FAD or late-onset sporadic AD (O’Neill et al., 1994;
Shaked et al., 2009), but several studies suggest that Gαo-
specific responses are progressively disrupted in both familial
and late sporadic forms of the disease. For example, using
membrane preparations from human brain samples, Reis et al.
(2007) found that the effects of FAD-APP-derived peptides
on G protein activity were blocked by PTX, while another
report showed that Aβ peptides could activate Gαo in lipid
vesicles (Rymer and Good, 2001), although it is unclear whether
the topology of these assays recapitulates authentic Gαo-Aβ
interactions. More compelling are two studies showing that
APP-Go signaling might be directly altered by neurotoxic Aβ
in neurons. Based on previous evidence that APP can bind
neurotoxic Aβ fibrils (Lorenzo et al., 2000; Van Nostrand et al.,
2002), Lorenzo et al. (2000) also showed that APP overexpression
rendered hippocampal neurons more vulnerable to Aβ-induced
degeneration, an effect that was abrogated by deletion of the
Go-binding domain in APP or treatment with PTX (Sola Vigo
et al., 2009). Notably, expressing a PTX-insensitive form of
Gαo restored the toxic effects of Aβ treatment, but only in the
presence of an intact Go-binding domain. Subsequent work by
Masliah and colleagues demonstrated that treatment with Aβ
reduced APP-Gαo interactions (corresponding to Go activation)
and induced cell death in transfected neuroblastoma lines, and
again this effect was PTX-dependent (Shaked et al., 2009).
Aβ treatment also provoked a significant increase in calcium
(Ca2+) influx in a Go-dependent manner, consistent with earlier
studies suggesting that hyperactivation of APP signaling could
provoke Ca2+ overload and cell death. Most notably, they showed
that APP-Gαo interactions declined in patients suffering from
progressive stages of AD, corresponding to an overall increase in
G protein activation (though not specifically Gαo).
In the course of their cell culture assays, the authors found
that mutating a particular residue within the cytoplasmic domain
of APP (D664A) blocked the ability of Aβ to affect APP-Gαo
interactions (Shaked et al., 2009). Noting that this residue is
required for caspase-dependent cleavage of APP to generate
a cytotoxic C31 fragment (Lu et al., 2003), they proposed a
mechanism by which Aβ binding induces caspase-dependent
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cleavage of APP, resulting in the release of a C31-Go complex that
could stimulate Gαo in some undefined fashion. However, other
investigators have noted that the D664A mutation (located within
the Go domain) is equally likely to disrupt interactions between
APP and other cytoplasmic proteins (Galvan et al., 2007), the
most obvious candidate being Gαo. Thus, mutations at this site
might perturb key structural features that permit APP to function
as a Go-coupled receptor, although the steric rearrangements that
lead to the activation of Gαo remain unexplored. Paradoxically,
Shaked et al. (2009) also reported that deletion of the C-terminal
YENPTY domain mitigated the effects of Aβ on Gαo activation,
contradicting several previous studies demonstrating that this
motif is not required for direct interactions between APP and
Gαo (Nishimoto et al., 1993; Kawasumi et al., 2004; King
and Scott Turner, 2004; Sola Vigo et al., 2009). Nevertheless,
these results offered the most compelling evidence that APP-
Go signaling is altered over the course of AD, consistent with
the model that elevated Aβ might induce the aberrant activation
of Gαo-dependent pathways that provoke neuropathological
responses.
Recently, Fogel et al. (2014) used fluorescence resonance
energy transfer (FRET)-based protocols to demonstrate a
close association between APP and Gαo that was modulated
by APP activation. They also showed that Aβ40 induced
structural rearrangements in the presynaptic APP/Go complex
by promoting APP dimerization, which in turn resulted in G
protein-dependent Ca2+ influx and glutamate release (Fogel
et al., 2014). Both aspects of this response were found to
critically involve the E1 extracellular domain of APP, suggesting
that Aβ40 can mimic the effects of endogenous ligands. Based
on these findings, the authors proposed that excessive APP
activation by amyloid peptides might contribute to hippocampal
hyperactivity under pathological conditions, supporting the
hypothesis that normal APP-Gαo interactions are altered in
AD. An added dimension to this model is that Gαo may also
functionally interact with presenilins, essential components of
the γ-secretase complex that are involved in generating Aβ
peptides and AICD fragments and are also mutated in some
forms of FAD (Walter et al., 2001; Jayne et al., 2016). For
example, Smine et al. (1998) showed that presenilin-1 (PS-
1) could be co-immunoprecipitated with Gαo (but not Gαi2)
when overexpressed in COS-7 cells, and that a C-terminal
fragment (CTF) of PS-1 could activate Gαo (but not Gαi2) in
a PTX-sensitive manner. Likewise, overexpressing FAD mutant
forms of Presenilin-2 (PS-2) in neuroblastoma cells induced
apoptotic responses that were inhibited by PTX and restored
by expressing a PTX-resistant variant of Gαo but not Gαi
(Wolozin et al., 1996; Abe et al., 2004). Whether presenilins
actually modulate Gαo-dependent pathways in neurons and how
this might affect APP-Gαo interactions remains to be explored.
Nevertheless, it is possible that multiple factors associated
with AD might contribute to the pathological misregulation
of APP-Gαo signaling (including FAD-linked mutations in
both APP and the presenilins), as well as the accumulation
of neurotoxic amyloid peptides that can hyperactivate this
pathway.
STRUCTURE, SPECIFICITY, AND
EVOLUTIONARY CONSERVATION OF
THE Go-BINDING DOMAIN IN APP
FAMILY PROTEINS
As noted earlier, Nishimoto et al. (1993) first identified the
G protein-binding domain in APP, based on their previous
discoveries that several type-1 transmembrane proteins directly
bind Gα subunits via short peptide sequences containing BBXB
or BBXXB motifs, where B is a basic amino acid residue and X
is any non-basic residue (Okamoto et al., 1990, 1991; Okamoto
and Nishimoto, 1992). From this analysis, they identified “peptide
20” in APP695 (H657-L676), which contains two N-terminal basic
residues (HH) and terminates in a BBXXB motif (Figure 1A;
magenta region). In a meticulous series of experiments using
reconstituted liposomes and isolated membrane fractions, they
then showed that this “peptide 20” domain (subsequently
designated the Go activator domain) was both necessary and
sufficient for directly binding and activating Gαo, but not Gαs,
Gαi1, Gαi2, or Gαi3 (Table 1). Removing either the N-terminal
histidines (Figure 1A, asterisks) or the C-terminal BBXXB motif
from peptide 20 (RHLSK) greatly attenuated its ability to simulate
Gαo in GTPase activation assays, although membrane-tethered
versions of the Go domain were considerably more potent
than soluble forms. Thirdly, they demonstrated that interactions
between full-length APP and Gαo required this domain: a
deletion that removed both the Go domain and the C-terminal
YENPTY motif precluded APP-Gαo interactions (His657-N695;
Figure 1B1), whereas a deletion encompassing only the YENPTY
did not (Figure 1B2). These results provide strong evidence that
the juxtamembrane G protein-binding domain in APP promotes
functional interactions with Gαo but not other G proteins
(Nishimoto et al., 1993).
Using similar methods, Nishimoto et al. (1993) subsequently
showed that full-length APP binds and stimulates Gαo (but
not Gαi2) following antibody activation in reconstituted vesicles
(Okamoto et al., 1995; Ikezu et al., 1996), while the apoptotic
effects of FAD-APP isoforms (mutated at V642) were both PTX-
sensitive and required the Go domain: FAD-APP constructs
lacking only the Go domain (Figure 1B3) failed to induce Gαo-
dependent cytotoxic responses, whereas deletions encompassing
the YENPTY domain (Figure 1B2) had no effect (Okamoto
et al., 1996; Yamatsuji et al., 1996a; Hashimoto et al., 2000;
Niikura et al., 2000; Sudo et al., 2001). This apoptotic response
could also be blocked with dominant-interfering forms of
Gαo (GαoG204A) but not Gαi2 (Table 1; Yamatsuji et al.,
1996b). Using Myc-tagged constructs for in vitro pull-down
assays, Brouillet et al. (1999) subsequently confirmed that the
cytoplasmic domain of APP could bind Gαo but not Gαi2,
and that this interaction was reduced when the N-terminal
H657H658 doublet was replaced with hydrophobic residues.
Sudo et al. (2001) and Hashimoto et al. (2003a) then showed
that that apoptotic effects of APP stimulation were prevented
by deleting the Go interaction domain (Figure 1B3) but
not the YENPTY domain (Figure 1B2), and that they were
mediated specifically by Gαo but not Gαi. Similarly, based
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on evidence that Aβ might induce neurotoxic responses via
the APP-Gαo pathway, Lorenzo and colleagues showed that
this effect also required the Go domain (Sola Vigo et al.,
2009): deleting the entire cytoplasmic domain (Figure 1B4)
precluded the activation of Gαo-dependent responses to Aβ, as
did complementary deletions targeting different portions of the
Go domain (Figure 1B5,6), whereas a deletion encompassing the
YENPTY motif did not (Figure 1B7). In a more physiological
context, the Kögel group recently demonstrated the importance
of the Go domain in mediating APP-dependent neuroprotective
responses to sAPPα: a deletion that removed the conserved
PEERH motif within this domain (Figure 1B9) prevented APP-
dependent signaling that was also blocked by PTX (implicating
Gαo/i proteins), whereas two different deletions targeting the
YENPTY motif (Figure 1B10,11) had no effect (as summarized
below).
In contrast to the foregoing studies, Shaked et al. (2009)
reported that Gαo could still be co-immunoprecipitated
with APP lacking the C31 cytoplasmic region (including
both the Go-binding domain and the YENPTY motif;
Figure 1B12), but that deleting this region prevented APP-
dependent activation of Gαo pathways in cell culture. They
also found that over-expressed C99 fragments could be
co-immunoprecipitated with Gαo (the only report of this
interaction). Curiously, deletion of only the YENPTY motif
(Figure 1B13) also blocked Gαo-dependent responses in
this assay, in contrast to many other studies demonstrating
that this domain is not required for APP-Gαo interactions.
Based on these observations, the authors postulated that
the transduction of APP-Gαo signaling might involve the
YENPTY motif as well as the Go domain (either directly
or indirectly), possibly in response to Aβ-induced cleavage
of APP (Shaked et al., 2009). Whether this response also
involves internalization responses mediated by the YENPTY
motif remains to be explored (cf. Lai et al., 1995; Deyts et al.,
2016b).
Other members of the APP family also contain Go-like
domains, albeit with some sequence variations (Figure 1C).
Both APLP1 and APLP2 contain only one N-terminal histidine
that aligns with the HH doublet in APP695 (highlighted in
yellow), and only APLP2 also possesses an intact C-terminal
BBXXB motif (boxed region). As summarized above, only
APP695 has been shown to activate Gαo, although a rigorous
analysis of potential interactions between APLP1/2 and Gαo
has not been conducted in vivo. Likewise, the Go domains
in both nematode APL-1 and insect APPL contain only a
single N-terminal histidine and lack complete BBXXB motifs.
Nevertheless, studies in several insect models have shown that
APPL does functionally interact with Gαo both in vitro and
in vivo, whereby deleting different portions of the Go domain
in APPL (Figure 1D1,2) disrupted Gαo-associated responses in
the developing nervous system (Torroja et al., 1999b; Ramaker
et al., 2013; and described below). How these structural variations
within the Go domain might affect the dynamics of Gαo
activation/inactivation under physiological conditions remains to
be explored.
PHYSIOLOGICAL ROLE OF APP-Gαo
INTERACTIONS IN STRESS SIGNALING
AND NEUROPROTECTION
Based on early work suggesting that APP might regulate both
cell adhesion and excitoprotective responses (Mattson et al.,
1993; Schubert and Behl, 1993), a variety of in vitro and in vivo
assays demonstrated that both full-length APP and its sAPPα
ectodomain fragments (produced by α-secretase cleavage) could
have potent neuroprotective activity under different conditions
(reviewed in Kögel et al., 2012; Nhan et al., 2015). For
example, deletion of the sole APP ortholog in nematode (APL-1)
caused larval lethality that could be rescued by expressing
extracellular domain fragments equivalent to sAPPα (Hornsten
et al., 2007; Ewald et al., 2016), while overexpressing sAPPα
rescued some behavioral deficits in mice lacking members of the
APP family (Ring et al., 2007; Weyer et al., 2011). From these
and other experiments emerged a complex scenario whereby
both APP and sAPPα might independently confer beneficial
responses under physiological conditions. However, elevated
sAPPα levels can also have unwanted effects on cell proliferation
and tumorigenesis, potentially due to interactions with receptors
whose roles in neuroprotection is unclear (Adlerz et al., 2007;
Zhou et al., 2011). More recently, Kögel and colleagues have
provided new evidence that transmembrane APP and sAPPα
interact as a ligand/receptor pair in neurons to modulate stress
signaling, via activation of the pro-survival PI3K/Akt pathway
(Milosch et al., 2014). Using a variety of experimental strategies,
they demonstrated that both APP and sAPPα antagonize the
activation of the JNK-dependent stress signaling pathway, which
(as noted earlier) is a key upstream modulator of mitochondria-
dependent apoptosis (Kögel et al., 2005; Copanaki et al., 2010;
Eckert et al., 2011). Conversely, several groups have now shown
that the protective function of APP requires activation of the
PI3K/Akt pathway (Cheng et al., 2002; Copanaki et al., 2010;
Eckert et al., 2011; Jimenez et al., 2011). Since Akt negatively
regulates several JNK-activating kinases, including ASK1 and
mixed lineage kinase 3 (MLK3), these findings suggest that
APP modulates a dynamic interplay between stress and survival
pathways (Kögel et al., 2012).
To define the role of full-length APP in this response,
Milosch et al. (2014) showed that the protective effects of both
sAPPα and a recombinant fragment containing only the E1
domain of APP were completely abrogated in neurons from
APP knockout animals or in APP-depleted SH-SY5Y cells. These
results clearly demonstrated that expression of membrane-bound
holo-APP was required for sAPPα-dependent Akt activation and
neuroprotection in these assays, supported by other evidence that
sAPPα can regulate the dimerization of transmembrane APP in
cell culture (Gralle et al., 2009; Kaden et al., 2012). Likewise,
studies in Drosophila have shown that sAPPL ectodomain
fragments (equivalent to sAPPα) bind full-length APPL, and
that the neuroprotective effects of sAPPL require the presence
of the holoprotein (Wentzell et al., 2012). More recently, a
behavioral analysis demonstrated that full-length APPL and
secreted sAPPLα act together to promote memory formation in
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adult Drosophila (Bourdet et al., 2015), consistent with the model
that APP-sAPPα interactions may serve a variety of physiological
functions in the nervous system.
Although the foregoing experiments demonstrated
that the C-terminal domain of APP was required for the
neuroprotective effects of the holoprotein, the last 15 amino
acids were dispensable (as summarized in Figure 1B8−11):
sAPPα-dependent activation of Akt was unaffected in neurons
from APP-1CT15 mice, which express a mutant form of APP
lacking the cytoplasmic YENPTY motif (Milosch et al., 2014).
As noted in other reviews, this domain mediates interactions
with a plethora of cytoplasmic proteins but not Gαo (Nishimoto
et al., 1993; King and Scott Turner, 2004; Sola Vigo et al., 2009).
To further map the specific regions in APP that are required
for this activity, APP-KO cells were transfected with an APP
construct lacking the PEER motif within its Go-binding domain
(1PEERH). In contrast to the YENPTY mutant, the 1PEERH
mutant did not rescue sAPPα-induced Akt activation following
trophic factor deprivation. In addition, treatment with PTX
completely abolished the ability of sAPPα to promote Akt
activation and cell survival, further implicating a role for Go
in this response. Lastly, activation of the PI3K/Akt pathway by
sAPPα induced the phosphorylation of glycogen synthase kinase
3β (GSK3β), which is a well-known mechanism for inhibiting
GSK3β-induced apoptotic responses (Watcharasit et al., 2003;
Hanumanthappa et al., 2014). Whereas PI3K/Akt signaling
was originally linked with receptor tyrosine kinase activation,
numerous studies have shown that heterotrimeric G proteins
also play a critical role in regulating PI3K activity under both
physiological and pathological conditions (Murga et al., 1998;
Murga et al., 2000; New and Wong, 2007; Yanamadala et al.,
2009). Since PTX selectively inhibits members of the Gαo/i
family, while APP only interacts with Gαo and potentially
Gαs (as noted below), these results argue that APP/sAPPα
interactions induce the PI3K/Akt pathway specifically via Gαo.
Based on these findings, we propose that transmembrane
APP mediates sAPPα-induced neuroprotection via Gαo-coupled
activation of the PI3K/Akt pro-survival pathway (Figure 2A).
In turn, activation of Akt phosphorylates and inhibits GSK3β,
as well as other pro-apoptotic targets (Datta et al., 1997; Endo
et al., 2006; Jover-Mengual et al., 2010). We also propose that this
response requires direct interactions between sAPPα and holo-
APP as a ligand-receptor pair. These results offer a resolution to
paradoxical findings from previous investigations, demonstrating
that holo-APP and sAPPα are equally important in mediating
neuroprotective responses. Conversely, factors that interfere with
this function would render neurons more susceptible to cellular
stress during brain aging and AD. The model that APP-Gαo
signaling serves a neuroprotective function under physiological
conditions contrasts with the cytotoxic response elicited by
hyperactivating this pathway in AD models (as summarized
above). Of note is that treatment with Aβ might also interfere
with the neuroprotective effects of sAPPα, resulting in the
disinhibition of GSK3β and consequent upregulation of apoptotic
pathways (Jimenez et al., 2011). Since GSK3β activity is increased
in the AD brain (Crews and Masliah, 2010; Jimenez et al., 2011;
Llorens-Martin et al., 2014), we hypothesize that the decline
in sAPPα levels associated with both sporadic AD and FAD
contributes to this phenomenon (Almkvist et al., 1997; Sennvik
et al., 2000), thereby promoting tau hyperphosphorylation (Deng
et al., 2015) and sensitizing neurons to stress and apoptosis. In
summary, these studies provide new insight into the mechanisms
by which APP-Go signaling regulates neuronal stress responses
under physiological conditions, and how the loss of this function
might render neurons more susceptible to cellular stress during
normal brain aging and AD.
APP-Gαo SIGNALING IN THE CONTROL
OF NEURONAL MOTILITY: VIEWS FROM
A NON-MAMMALIAN SYSTEM
Although APP was originally identified in humans, it is actually
a member of an evolutionarily ancient family of proteins that
may serve similar roles in the developing nervous systems
of many organisms (Coulson et al., 2000; Ewald and Li,
2012; Lazarov and Demars, 2012; Shariati and De Strooper,
2013). Studies using a variety of insect models have shown
that APPL shares both structural and functional conservation
with human APP695, including homologous extracellular and
intracellular motifs that regulate interactions with other proteins
(Cassar and Kretzschmar, 2016). In particular, several groups
have demonstrated a role for APPL-Gαo signaling in neuronal
development. Using genetic methods, Torroja et al. (1996,
1999a) first showed that APPL plays an important role in
regulating neuronal growth and maturation, and that this
activity requires the conserved Go-binding domain shared by
APP695 and APPL. Replacing endogenous APPL with a mutant
form lacking this domain (Figure 1D1) disrupted the normal
maturation of synaptic boutons at the neuromuscular junction,
potentially caused by the loss of ligand-dependent APPL-Go
signaling (Torroja et al., 1999b). Subsequent investigations into
this response suggested a role for the homophilic cell adhesion
receptor Fasciclin II (Fas II; the insect ortholog of NCAM),
whereby trans-synaptic interactions mediated by Fas II could
promote APPL signaling, in part via the activation of Gαo.
Whether Fas II acts as a ligand as well as a co-receptor for APPL
remains to be explored, as does the role of downstream Gαo
effectors in regulating synaptic maturation. Nevertheless, this
work offered compelling evidence that the APP-Go pathway is
conserved in both invertebrate and vertebrate nervous systems.
Using Manduca sexta (tobacco hornworm) as a
complementary model, the Copenhaver laboratory has also
explored the role of APPL-Gαo signaling in the developmental
control of neuronal motility. Unlike Drosophila, the formation
of the embryonic nervous system in Manduca involves an
extended period of neuronal migration (Copenhaver and
Taghert, 1989; Copenhaver, 2007), analogous to the more
complex waves of migration that typify mammalian brain
development (Ayala et al., 2007; Tabata and Nagata, 2016).
Notably, APPL colocalizes with Gαo in the leading processes
and growing axons of migratory neurons in Manduca (Swanson
et al., 2005), similar to the colocalization of APP and Gαo
in cultured mammalian neurons (Ramaker et al., 2013).
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FIGURE 2 | APP-Go signaling can regulate alternative downstream pathways in a context-dependent manner. (A) APP is inserted into the plasma
membrane of neurons as a type-1 transmembrane protein that directly interacts with the heterotrimeric G protein Go; the major fraction of the holoprotein
spontaneously forms homodimers under unstimulated conditions. Interactions with sAPPα ectodomain fragments (generated by α-secretase processing) promotes
the dissociation of homodimeric APP and activates Gαo, stimulating the exchange of bound GDP for GTP on the Gαo subunit and its dissociation from the Gβγ
dimer (similar to signaling by conventional GPCRs; Fogel et al., 2014). Both activated Gαo and Gβγ may stimulate PI3K, which then phosphorylates and activates
Akt. In turn, Akt phosphorylates and inhibits downstream targets linked with apoptotic responses and Tau hyperphosphorylation, including GSK3β and components
of the stress kinase pathway that regulate JNK (Kögel et al., 2003; Copanaki et al., 2010). In this manner, stimulation of the APP-Gαo pathway by sAPPα promotes
neuroprotective responses by modulating neuronal stress signaling, providing a mechanism for integrating the stress and survival responses regulated by APP and
its cleaved sAPPα ectodomain fragments (Kögel et al., 2012; Milosch et al., 2014). (B) In the developing nervous system of Manduca, migratory neurons co-express
insect APP (APPL) and Gαo in their leading processes (Swanson et al., 2005; Ramaker et al., 2013), while their ensheathing glial cells express a single Contactin
ortholog (MsContactin). Embryo culture assays have shown that glial Contactin stimulates APP-Go signaling in the migratory neurons, whereby Gαo-dependent
induction of Ca2+ currents (and possibly other effectors regulated by via Gβγ) induces local retraction responses that prevent ectopic migration and outgrowth
(Horgan and Copenhaver, 1998; Ramaker et al., 2016b). (C) Membrane-tethered AICDs and APP-CTFs can also interact with Gαs to stimulate neuronal motility and
outgrowth, via a pathway that involves the activation of adenylate cyclase/cAMP/PKA/CREB signaling, accompanied by the phosphorylation/inactivation of GSK3β
(Deyts et al., 2012, 2016a). Stimulation of APP signaling by different combinations of ligands and co-receptors might preferentially activate Gαo- or Gαs- associated
responses in a context-dependent manner, whereby APP-G protein signaling can either promote or inhibit neuronal motility at specific stages and locations in the
nervous system.
In addition, co-immunoprecipitation assays showed that
endogenously expressed APPL and Gαo functionally interact
in a manner that is regulated by Gαo activation (Ramaker
et al., 2013). By co-expressing fusion constructs of APPL and
Gαo containing complementary portions of Venus fluorescent
protein in transfected COS7 cells, bimolecular fluorescence
complementation (BiFC) assays were used to demonstrate that
transmembrane APPL directly bound Gαo (but not Gαi or Gαs),
while APP695 also directly bound Gαo, similar to conventional
GPCRs (Marinissen and Gutkind, 2001; Oldham and Hamm,
2008). More importantly, expressing these constructs in
transgenic Drosophila lines revealed that APPL bound Gαo in
healthy neurons, providing the first demonstration of direct
interactions between an APP family protein and Gαo in vivo.
Notably, this interaction could be readily visualized within
synaptic regions of the brain by BiFC, whereas deleting the Go
domain in APPL (Figure 1D2) eliminated APPL-Gαo binding
(Ramaker et al., 2013). In combination, these studies substantiate
the model that APP family proteins can indeed function as
unconventional GPCRs, specifically regulating Gαo-dependent
responses.
By adapting an embryo culture assay that permits targeted
manipulations of migratory neurons in Manduca (Horgan and
Copenhaver, 1998), the Copenhaver laboratory subsequently
showed that APPL-Gαo signaling plays an important role in
regulating neuronal motile behaviors: inhibiting either APPL
expression or Gαo activity induced a distinctive pattern of ectopic
growth and migration, while hyperstimulating the APPL-Gαo
pathway induced collapse-stall responses (Ramaker et al., 2013).
These effects were analogous to the striking pattern of ectopic
neuronal migration reported in the brains of mice deleted for all
three APP family proteins (Herms et al., 2004), and recapitulated
earlier studies in Manduca showing that activated Gαo inhibits
migration via the induction of voltage-independent currents
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(Horgan et al., 1995; Horgan and Copenhaver, 1998). More recent
studies have identified Manduca Contactin (MsContactin) as a
candidate ligand for APPL (Ramaker et al., 2016b). Specifically,
experiments in cultured embryos indicated that GPI-linked
MsContactin (expressed by adjacent glial cells) activates APPL-
Gαo signaling in the migratory neurons to induce local retraction
responses (Figure 2B), thereby preventing ectopic outgrowth.
This discovery was supported by reports that multiple Contactin
family members in mammalian systems can interact with APP
and its orthologs both in cis and trans (Ma et al., 2008; Osterfield
et al., 2008; Tachi et al., 2010; Osterhout et al., 2015). In
summary, our experiments provide new evidence that APP
family proteins regulate key aspects of neuronal development
during embryogenesis, in part via activation of Gαo-dependent
pathways. Still to be determined are the downstream effectors
that transduce the effects of APPL-Gαo signaling on neuronal
behavior. Likewise, whether mammalian Contactins might
regulate APP-Gαo signaling in migratory cortical neurons, and
whether modulation of the PI3K-Akt pathway or GSK3β activity
also contributes to this response within the developing nervous
system remains to be explored (e.g., Morgan-Smith et al., 2014).
APP MAY ALSO REGULATE NEURONAL
MOTILITY via Gαs-DEPENDENT
PATHWAYS
Most studies support the model that transmembrane APP
normally binds and activates Gαo in response to a variety of
ligands (including sAPPα and MsContactin), suggesting that APP
cleavage (by secretases or caspases) is likely to terminate APP-
Gαo signaling rather than activating it. In support of this model,
we recently showed that blocking α-secretase activity in the
migratory neurons of cultured Manduca embryos significantly
increased membrane-associated APPL levels, while inducing the
same collapse/stall responses caused by hyperactivating APPL-
Gαo signaling with Contactin fusion proteins (Ramaker et al.,
2016a,b). Likewise, our analysis of endogenously expressed
APP family proteins showed that Gαo could be readily co-
immunoprecipitated with both full length APP695 (from mouse
and human brain lysates) and APPL (from Manduca and
Drosophila lysates), whereas we did not detect their CTF or AICD
fragments in the immunoprecipitated complexes (Ramaker et al.,
2013). These results are also consistent with past work focusing
on the functional interactions between transmembrane APP695
and Gαo (e.g., Okamoto et al., 1995; Hashimoto et al., 2003a;
Sola Vigo et al., 2009). However, as noted above, several reports
have shown that Gαo can also interact with membrane-tethered
peptide 20 domains (mimicking CTFs that contain the Go-
binding domain), and one study showed that Gαo could be co-
immunoprecipitated with C99 fragments (normally generated by
β-secretase cleavage) when overexpressed in neuroblastoma cells
(Shaked et al., 2009). Whether Gαo actually continues to interact
with CTFs following α- or β-cleavage of the holoprotein in
neurons, and whether these interactions might affect downstream
pathways regulated by APP-Gαo signaling under physiological
conditions, is still unknown.
In contrast, recent studies by Parent and colleagues have
indicated that a different G protein (Gαs) may be activated
by CTFs derived from the APP holoprotein (Deyts et al.,
2012). Specifically, they found that overexpressing a membrane-
tethered AICD construct (mAICD) or experimentally elevating
intracellular APP-CTF levels dramatically increased neurite
outgrowth in both neuroblastoma cells and transfected cortical
neurons. This response required AC-dependent activation of
protein kinase A (PKA) and corresponded to the phosphorylation
of two PKA targets (CREB and GSK3β), both of which can
regulate neuronal motility. To test the involvement of Gαs (a
canonical activator of AC), they also showed that HA-tagged Gαs
could be co-immunoprecipitated with mAICD from transfected
cells, whereas dominant-negative Gαs (lacking its palmitoylation
site) prevented mAICD-induced outgrowth. Focusing on the
BBXXB motif in APP that was originally identified by Nishimoto
et al. (1993) (Figure 2C, asterisks), Deyts et al. (2012) found that
mutating this site prevented interactions between the mAICD
construct and HA-Gαs. Curiously, they also demonstrated an
interaction between Gαs and an equivalent construct derived
from APLP1, which (like insect APPL) lacks a BBXXB motif
(Figure 1C, boxed region), suggesting that this motif may not be
strictly required for functional interactions between APP family
proteins and Gα subunits within intact neurons.
More recently, the Parent group conducted a series of carefully
controlled experiments in both cultured neurons and transgenic
mice, demonstrating that elevating APP-CTF levels (by a variety
of methods) induced exuberant neurite outgrowth, coincident
with enhanced PKA and CREB phosphorylation (Deyts et al.,
2016a). Consistent with their earlier work, they found that
overexpressing β-CTF fragments of APP (C99) also stimulated
outgrowth, whereas a C99 construct with a mutated BBXXB
motif did not. Lastly, they showed that treatment with an AC
inhibitor prevented increased outgrowth and phosphorylated
CREB levels in their assays, again implicating Gαs-dependent
signaling. Whether Gαs endogenously interacts with APP-CTFs
in healthy neurons and whether this interaction is perturbed over
the course of AD remains to be explored. Nevertheless, given
available evidence that Gαo normally interacts with full-length
APP but not its fragments in neurons (as summarized above),
these results support the intriguing view that APP cleavage
might induce a novel type of G protein switching (Tucek et al.,
2002; Woehler and Ponimaskin, 2009), whereby the holoprotein
signals as a transmembrane receptor specifically via Gαo, while its
CTF fragments can selectively regulate Gαs-dependent pathways
(Figure 2C). In the context of neuronal development, this
model might also help explain how APP-dependent signaling can
promote neuronal motility in some contexts while restricting it in
others.
CONCLUSION AND PERSPECTIVE:
LIGAND-DEPENDENT MODULATION OF
APP-Gαo SIGNALING
Despite considerable efforts to establish a role for aberrant APP-
Gαo signaling in AD, proof for this model has been hindered
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by incomplete understanding of the mechanisms that normally
regulate this pathway in the brain. Because past studies
often relied on rather artificial assays and overexpression
systems, it is still unclear whether hyperstimulating this
pathway results in the misregulation of endogenous signaling
responses or produces novel gain-of-function effects that
normally do not occur in the brain. Our laboratories have
now approached this issue using complementary strategies,
with the goal of understanding how this evolutionarily
conserved signaling pathway regulates neuronal functions
in both the developing and mature nervous system. As
summarized in Figure 2A, sAPPα ectodomain fragments
are clearly able to activate the PI3K/Akt pathway and
modulate neuronal stress signaling, a response that undoubtedly
plays important roles in both the developing and adult
brain (Kögel et al., 2012; Milosch et al., 2014). By
comparison, Contactin-dependent activation of APP-Go
signaling can regulate the motile behavior of developing
neurons (Figure 2B), in part by modulating Ca2+ influx and
downstream effectors that modulate cytoskeletal dynamics
(Horgan and Copenhaver, 1998; Copenhaver and Ramaker,
2016). Evidence that CTF fragments might also regulate
neuronal behavior via Gαs (Figure 2C) suggests that G
protein switching could also contribute to the refinement
of APP-dependent motile responses (Deyts et al., 2012,
2016a).
We postulate that our different experimental preparations
have revealed an important aspect of APP-Go signaling:
namely, that the integration of this pathway with alternative
or complementary effectors can be strongly influenced by
particular combinations of ligands and co-receptors for APP
that are expressed in a context-dependent manner. As has been
reviewed elsewhere, APP family proteins can interact with a
wide variety of candidate binding partners (Hoe et al., 2009;
Jacobsen and Iverfeldt, 2009; Rice et al., 2013; Deyts et al.,
2016b), although most of these interactions have yet to be
validated in vivo. For example, experiments using cultured
neurons have shown that stimulation with sAPPα can promote
APP-dependent outgrowth via interactions with members of the
integrin and L1CAM families (Osterfield et al., 2008; Young-
Pearse et al., 2008), a response that can be further modulated
by extracellular proteins like Reelin, F-spondin, and Semaphorin
3A (Ho and Sudhof, 2004; Hoe et al., 2009; Magdesian et al.,
2011). More recently, elegant work by Young-Pearse and
colleagues showed that different members of the pancortin
family can both promote and inhibit APP-dependent responses
in migrating cortical neurons, possibly via a combination of
direct and indirect interactions (Rice et al., 2012). Whether
these interactions also regulate Go-dependent aspects of motility
remains to be explored. Outside the nervous system, APP
family proteins are strongly upregulated by keratinocytes during
wound healing (Herzog et al., 2004), while treatment with
sAPPα stimulates their motile behavior (Kirfel et al., 2002),
although it is unclear if this response is transduced by APP
or other receptors. From a developmental perspective, ample
precedent for this model of APP-Go signaling can be found
in the responses elicited by other neuronal guidance receptors
that can both stimulate and inhibit outgrowth, depending on
a variety of interacting factors (Nishiyama et al., 2003; Egea
and Klein, 2007; Yoshida, 2012; Finci et al., 2014; Kaplan
et al., 2014). Likewise, whether activation of APP-Gαo signaling
induces neuroprotective or neurotoxic responses might be
strongly affected by convergent input from physiological stimuli
(particularly sAPPα) or pathological factors (including Aβ42
oligomers).
Lastly, it should be noted that APP expression is significantly
altered in a variety of other diseases besides AD. In Down
syndrome (DS), trisomy 21 results in a triplication of the
gene encoding APP (as well as many other genes; Antonarakis
et al., 2004), and most DS patients exhibit accelerated Aβ
accumulation and develop AD-like neurological pathologies
(Millan Sanchez et al., 2012; Castro et al., 2016). APP
expression is also dramatically upregulated in the brain
following traumatic brain injury (Plummer et al., 2016; Acosta
et al., 2017) and in lesions associated with epilepsy and
multiple sclerosis (Noebels, 2011; Matias-Guiu et al., 2016).
Whether APP serves a neuroprotective function or promotes
degenerative responses in these diseases is still unknown;
hence, determining how APP-Gαo signaling is altered in
AD should also be relevant to other conditions in which
this pathway might be misregulated. Only by fully defining
the normal mechanisms of APP-Go signaling in the brain
will it be possible to resolve how the misregulation of this
pathway may contribute to the pathological sequelae that give
rise to AD.
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